NDA 212268 · Hisamitsu
Secuado
Asenapine · Transdermal · Atypical Antipsychotic
Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Oct 11, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
51
35 Phase 3, 0 recruiting
FAERS reports
912
722 serious, 139 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SECUADO is not approved for the treatment of patients with dementia-related psychosis [ see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SECUADO is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 )
What it is approved for
From the label in effect Jan 30, 2025.
SECUADO is indicated for the treatment of adults with schizophrenia [ see Clinical Studies (14) ]. SECUADO is an atypical antipsychotic indicated for the treatment of adults with schizophrenia. ( 1 )
Mechanism: The mechanism of action of asenapine in schizophrenia is unclear. However, it’s efficacy in schizophrenia could be mediated through a combination of antagonist activity at D 2 and 5-HT 2A receptors.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- SECUADO · ASENAPINE 5.7MG/24HR · SYSTEM, TRANSDERMAL · Prescription
- SECUADO · ASENAPINE 7.6MG/24HR · SYSTEM, TRANSDERMAL · Prescription
- SECUADO · ASENAPINE 3.8MG/24HR · SYSTEM, TRANSDERMAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Asenapine" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00212784 · 1,225 participants · Start Sep 4, 2003 · Primary completion Mar 15, 2006
Drug: asenapine; olanzapine · For: Schizophrenia; Schizoaffective Disorder
- To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00150176 · 831 participants · Start Apr 2005 · Primary completion Jun 2008
Drug: Asenapine - Open Label; Placebo - Double Blind and 1 more · For: Schizophrenia
- Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.Pivotal-lookingCompleted
Noven Pharmaceuticals, Inc.Industry
NCT02876900 · 617 participants · Start Aug 2016 · Primary completion Jun 2018
Drug: Low Dose Asenapine maleate transdermal patch; High Dose Asenapine maleate transdermal patch and 1 more · For: Schizophrenia
Sites: Jersey City, New Jersey
- Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01396291 · 561 participants · Start Dec 2011 · Primary completion Apr 2015
Drug: asenapine; placebo · For: Bipolar 1 Disorder
Sites: Anaheim, California; Chino, California; Escondido, California · 80 sites in all
- 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01098110 · 532 participants · Start May 25, 2010 · Primary completion Apr 14, 2014
Drug: Asenapine 5 mg; Asenapine 10 mg and 1 more · For: Schizophrenia
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00143182 · 504 participants · Start Jan 7, 2005 · Primary completion Jun 28, 2006
Drug: Asenapine; Olanzapine · For: Bipolar Disorder
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00159796 · 489 participants · Start Dec 14, 2004 · Primary completion Mar 28, 2006
Drug: Asenapine; Olanzapine and 1 more · For: Bipolar Disorder
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00159744 · 488 participants · Start Nov 30, 2004 · Primary completion Apr 29, 2006
Drug: Asenapine; Olanzapine and 1 more · For: Bipolar Disorder
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective115
- drug interaction87
- off label use74
- completed suicide73
- toxicity to various agents67
- myocarditis58
- sedation40
- depression36
- somnolence32
- suicidal ideation32
- product substitution issue31
- weight increased31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 11 |
| 2011 | 18 |
| 2012 | 20 |
| 2013 | 19 |
| 2014 | 66 |
| 2015 | 93 |
| 2016 | 88 |
| 2017 | 52 |
| 2018 | 28 |
| 2019 | 47 |
| 2020 | 45 |
| 2021 | 74 |
| 2022 | 101 |
| 2023 | 62 |
| 2024 | 49 |
| 2025 | 89 |
| 2026 | 50 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Secuado (Asenapine)
2024 spending
$6.1M
Beneficiaries
873
4,499 claims
Per beneficiary
$6,973
$48.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $565,151 |
| 2021 | $2,179,911 |
| 2022 | $3,738,479 |
| 2023 | $4,972,991 |
| 2024 | $6,087,666 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, et al. · Lancet 2013 · Comparative Study, Meta-Analysis
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S, Crippa A, Siafis S, et al. · Am J Psychiatry 2020 · Meta-Analysis
- Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.
Lin X, Siafis S, Tian J, et al. · CNS Drugs 2025 · Systematic Review, Meta-Analysis
- Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis.
Barton BB, Segger F, Fischer K, et al. · Expert Opin Drug Saf 2020 · Meta-Analysis, Systematic Review
Sponsor: Hisamitsu
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.